Plato Investment Management Ltd Sells 2,815 Shares of IQVIA Holdings Inc. $IQV

Plato Investment Management Ltd cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 21.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,150 shares of the medical research company’s stock after selling 2,815 shares during the period. Plato Investment Management Ltd’s holdings in IQVIA were worth $2,299,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA in the 4th quarter worth $27,000. Activest Wealth Management lifted its holdings in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Physician Wealth Advisors Inc. grew its position in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Finally, Westside Investment Management Inc. increased its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE IQV opened at $178.48 on Monday. The company has a fifty day moving average price of $170.14 and a 200-day moving average price of $200.95. The firm has a market cap of $29.79 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 1.72 and a beta of 1.18. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the company earned $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on IQV shares. Morgan Stanley set a $225.00 price objective on shares of IQVIA in a research note on Thursday. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.